Baili Tianheng Pharmaceutical

Sichuan Baili Tianheng Pharmaceutical Co., Ltd.
Company Overview:
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. was established in 1996, and is a modern high-tech pharmaceutical enterprise integrating R&D, production, and sales. The company currently holds production approvals for nearly 200 varieties and has over 60 new drug candidates under registration and development, mainly covering pediatrics, gynecology, respiratory, digestive, cardiovascular, chronic diseases, antiviral, anesthesia, parenteral nutrition, oncology, and other fields.
The company has four production enterprises (two preparation manufacturers, one API manufacturer, and one chemical raw material production enterprise), two marketing enterprises (Baili Tianheng and Lhasa Xinbo), and two new drug R&D centers (Seattle R&D company in the US and Chengdu R&D center in China).

Production Capacity:
The company is equipped with advanced hardware manufacturing facilities, and its production processes are fully modernized and automated. It has workshops with 100,000-class clean areas, and currently produces over 100 specifications across 10 dosage forms, including capsules, tablets, granules, lyophilized powder injections, traditional Chinese medicine extracts, large-volume injections, small-volume injections, syrups, and tinctures, all meeting national pharmaceutical technology requirements. The annual production capacity includes 700 million bags of granules, 240 million capsules, 170 million tablets, 7.5 million vials of lyophilized powder injections, 1 million bottles of syrup, 5 million bottles of large-volume injections, and 23 million bottles of small-volume injections.

R&D Strength:
Through over a decade of cultivation, the company has established an efficient R&D system for first-generic drugs and a competitive R&D system for innovative drugs. The company's new drug R&D center is a provincial-level enterprise technology center in Sichuan Province, equipped with advanced imported instruments and equipment such as high-performance liquid chromatographs, atomic absorption spectrophotometers, gas chromatographs, and laser particle size analyzers. The center has more than 170 professional R&D personnel, has established an effective incentive and constraint mechanism targeting first-generic drug development, and has built a complete and efficient R&D system from "medicine and project initiation," "pharmaceutical research," "clinical research," "pilot and industrialization research" to "registration management," which effectively integrates external R&D resources.

Development History:
2011-Present
2011: Completed joint-stock reform
2012: Chengdu R&D center relocated to Chengdu Tianfu Life Science Park
2014: Established North American biological drug R&D company (Seattle) Systimmune
2015: Started construction of API production base
2005-2010
2005: Invested in the establishment of Guorui Pharmaceutical, and in 2007 acquired assets of former Shule Pharmaceutical through auction
2006: Established Tianheng Pharmaceutical, and moved administrative headquarters to Chengdu Hi-Tech International Plaza
2006: Launched large-scale advertising for "Xinbo Chaihuang" to establish pediatric brand and market position
2010: Started second-phase construction of Baili Pharmaceutical
1999-2004
1999: "Xinbo Chaihuang" obtained production approval
2002: Production base relocated to Chengdu Cross-Strait Science and Technology Park and passed national GMP certification
2004: Company successively obtained production approvals for varieties such as "Haohao Huangqi," "Aobolin," and "Paisixin"
2004: Initially established nationwide RX and OTC marketing systems
1996-1998
1996: Company established in Wenjiang District, Chengdu
1998: First product "Xinbolin" launched to market, achieving sales of 2 million RMB in the same year